Startups
Immunai
https://immunai.comComprehensively mapping and reprogramming the immune system with single-cell biology and AI to power new therapeutic discoveries, accelerate drug development and improve patient outcomes
Summary
Total Funding
$313M
- Unknown (2024-09-26) $18.0M
- Series B (2021-10-27) $215M
- Series A (2021-02-01) $60.0M
- Seed (2020-05-14) $20.0M
Investors
- AstraZeneca Unknown
- Catalio Capital Management Series A
- Schusterman Family Investments Series A
- Viola Ventures (formerly Carmel Ventures) Series A
- Duquesne Family Office Series A
- TLV Partners Series A
- Dexcel Pharma. Series A
Full Company Profile
- Access details of the company management, and other intelligence on this company by registering for Seedtable